Journey Clinical provides licensed psychotherapists and eligible patients access to psychedelic-assisted psychotherapies, supplying clinicians with tools to deliver PAP and connecting patients to a medical team and network of licensed mental-health professionals. The company began with Ketamine-Assisted Psychotherapy (KAP) and plans to expand to other psychotherapeutic treatments as they are validated, researched, and approved for broader FDA use. Since opening its platform in February 2022, Journey Clinical has grown its KAP clinician network from 30 to about 700 and has treated over 1,000 patients nationwide. The company is co-founded by Jonathan Sabbagh (CEO) and Myriam Barthes (COO). Financially, Journey Clinical raised an $8.5M Series A, bringing total funding to roughly $12M. The company intends to use the funds to continue scaling its offerings across the U.S. Journey Clinical operates a decentralized clinic model that enables licensed psychotherapists to provide legal psychedelic-assisted psychotherapy, beginning with ketamine. The platform handles the pharmacology and access to prescribing clinicians while therapists deliver customized psychotherapy treatment plans. Therapists pay a $200 monthly membership for services including access to a prescriber, a white-label EHR, KAP training, a directory profile, and a peer community. Patients pay $250 for intake consultations and $150 for follow-up consultations. Journey says the market is disparate, with over a million licensed mental health professionals lacking the infrastructure and access to prescribers needed to offer these treatments. The team includes co-founder and CEO Jonathan Sabbagh, psychiatrist Kyle Lapidus MD, Ph.D., and Brigitte Gordon DNP.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2023